Abraham Poulose, MD
Retina Specialist · Leawood, KSNPI 1497753560
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $976 of the $1,118 with a category attached, or 87.3%. 15 manufacturers reported payments, led by Alcon at 27.3% of the total.
Across 27 payments — averaging $41.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$305
- Bausch & Lomb Americas Inc.$204
- Genentech USA, Inc.$187
- Optos, Inc.$141
- Amgen$60
- Carl Zeiss Meditec USA, Inc.$40
- plus $180 from 9 others
Across 3 payments — averaging $93,589 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$281K
What the payments were for
- Food & beverage$97687%
- Education$10%
- Entertainment$14113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 4 | $305 |
| Bausch & Lomb Americas Inc. | 5 | $204 |
| Genentech USA, Inc. | 4 | $187 |
| Optos, Inc. | 1 | $141 |
| Amgen | 1 | $60 |
| Carl Zeiss Meditec USA, Inc. | 2 | $40 |
| Novartis | 2 | $32 |
| AbbVie | 1 | $27 |
| Coherus Oncology, Inc. | 1 | $24 |
| Biogen | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Coopervision Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANORAMIC OPHTHALMOSCOPE$283
- OCT OPHTHALMOSCOPE$283
- Clareon$254
- NFC-700$141
- VABYSMO$126
How this compares
Too few retina specialist providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 212 | $7,081 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $5,174 |
| IlevroNepafenac | 11 | $5,021 |
| Ketorolac Tromethamine | 99 | $1,974 |
| Ofloxacin | 124 | $1,215 |
| ErythromycinErythromycin Base | 49 | $584 |
| Latanoprost | 67 | $511 |
| Timolol Maleate | 32 | $416 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 20 | $327 |
| Brimonidine Tartrate | 23 | $191 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $162 |
| Dorzolamide Hcl | 11 | $147 |
| Tobramycin | 25 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $27 | $5,17415 claims |
| NovartisIlevro | $32 | $5,02111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Kansason file to place this against a meaningful peer group, so we don't.
Other retina specialist in Leawood
- Javed SayedLeawood$8K
- Paul WeishaarWichita$17K
- Kumar DallaWichita$14K
- Michael VarenhorstWichita$10K
- David ChackoWichita$8K
- Brooke NesmithWichita$6K
- Alan HromasWichita$3K
- Mary ChampionPrairie Village$3K
- Radwan AjlanKansas City$2K
- Thomas WoltjerWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.